Catalyst

Slingshot members are tracking this event:

AstraZeneca's(AZN) Lynparza(olaparib) in metastatic breast cancer PDUFA date is set for the first quarter of 2018

Source Link:
https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-accepts-regulatory-submission-for-lynparza-in-metastatic-breast-cancer-and-grants-priority-review-18102017.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jan 12, 2018
Occurred Source:
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Lynparza, Metastatic Breast Cancer, Her2, Brca Gene Mutation, Olaparib, Parp Inhibitor
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.